CSL Limited Share Price Faces New Test After A$1.06 Billion Buyback Ends
CSL Limited completed an on-market buyback of 6.4 million shares for A$1.06 billion, ending near a low point for its stock, which last closed at A$119.88. The buyback follows delays in the CSL Seqirus spin-off and weaker U.S. flu vaccine demand. Interim CEO Gordon Naylor took over after an 81% drop in first-half profit. U.S. military vaccine mandate changes have added pressure on CSL’s vaccine business.